As legal cannabis transforms North America, a number of major industries are beginning to develop their own strategies for new potential products and services.
In the medical cannabis space, major pharmaceutical companies are collecting a growing body of evidence that suggests cannabis has a number of medical benefits. As big pharma begins to enter the cannabis industry, there is significant potential for top pharmaceutical companies to work together with stakeholders within the industry to develop cannabis-based medicines and treatments.
Research collected by CB2 Insights (CSE:CBII, OTCQB:CBIIF) indicates that cannabidiol (CBD) could be useful in treating a number of medical conditions, including epilepsy, multiple sclerosis, schizophrenia, migraines and arthritis. There are currently almost 400 active medical trials involving CBD around the world, with a number of major American companies like Pfizer and GW Pharmaceuticals Ltd getting involved.
According to CB2 Insights, legal cannabis in the United States could save approximately US$1.1 billion on Medicaid prescriptions each year. The company believes the availability of clinical evidence could provide the missing link between patients, physicians, and potential treatments. As major pharmaceutical companies begin to enter the cannabis space, they bring with them the medical data necessary to make informed healthcare decisions moving forward.
Click here to connect with CB2 Insights (CSE:CBII) for an Investor Presentation.
Request an Investor Kit:CB2 Insights
This infographic is sponsored by CB2 Insights (CSE:CBII, OTCQB:CBIIF). This infographic provides information that was sourced by the Investing News Network (INN) and approved by CB2 Insights in order to help investors learn more about the company. CB2 Insights is a client of INN. The company’s campaign fees pay for INN to create and update this infographic.
This infographic was created according to INN editorial standards to educate investors.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with CB2 Insights and seek advice from a qualified investment advisor.